Chronic kidney disease is a risk factor for cardiovascular disease by Swanepoel, CR
38
CHRONIC KIDNEY 
DISEASE IS A RISK 
FACTOR








    
Email:
xxxxxxxxxxx@sun.ac.za
Author: XX Swanepoel 
Chronic kidney disease (CKD) is common, 
harmful and treatable. There are no accurate statistics on the 
prevalence of kidney disease in South Africa but the world 
prevalence is estimated at approximately 10%. Patients with 
CKD have cardiovascular (CV) mortality rates as high as 50%. 
In addition to traditional risk factors, these patients are 
exposed to other non-traditional CV risk factors. It is 
important to stress that with the development of early CKD 
in the form of increasing albuminuria, even from within the 
normal range (a marker of endothelial dysfunction), the 
patient is at increased risk of coronary heart disease. 
“Reverse epidemiology” is the paradox where a high body 
mass index predicts a better long-term survival in patients 
with CKD on haemodialysis. Curiously these patients have 
increased infl ammatory markers and atherosclerosis. 
“Confounding by disease” or “reverse causality” is used to 
explain why the traditional relationship of increased 
cholesterol, increased LDL cholesterol and CV risk is not 
present (except in nephrotics) in CKD. 
The high phosphate level predisposes to calcium phosphate 
crystal deposition in the vessels and heart valves. The 
resultant arteriosclerosis produces the increased pulse wave 
velocity and systolic hypertension. Rapid valvular calcifi cation, 
aortic stenosis being a particular diffi culty, and early onset 
coronary artery calcifi cation occur. 
Arrhythmias are common and the long QT interval syndrome 
is particularly pertinent. The risk of acquired LQTS is 
increased by the administration of drugs. Cardiac troponin T 
is elevated in approximately 25% of asymptomatic patients 
with CKD.
The use of angiotensin converting enzyme inhibitors and 
angiotensin receptor blockers have been shown to reduce 
proteinuria and to slow the progressive loss of renal function 
seen in CKD. These agents also improve cardiac outcomes 
and reduce the incidence of stroke. 
Most trials on the management of coronary artery disease 
have excluded patients with renal disease, and it remains 
unclear whether the results obtained from these trails can be 
extrapolated to patients with CKD. 
ABSTRACT
INTRODUCTION                                                                 
Chronic kidney disease (CKD) is a condition in which a pathological 
process affects components of the kidney for longer than three months. 
When the diagnosis of CKD is made, glomerular fi ltration rate (GFR) 
may still be normal. The K/DOQI guidelines(1) of the US National Kidney 
Foundation have put forward a staging of CKD where stage 1 comprises 
a normal glomerular fi ltration rate (> 90 ml/min) and stage 5 or ESRD 
describes the patient with a GFR of < 15 ml/min (Table 1).
There are no accurate statistics on the prevalence of kidney disease in 
South Africa, but the literature suggests a prevalence of around 10% in 
the adult population throughout the world.(2)
CARDIOVASCULAR DISEASE IN PATIENTS WITH CKD
The Framingham data on cardiovascular disease (CV) risk factors, 
i.e. hypertension, smoking, diabetes, dyslipidaemia and left ventricular 
hypertrophy applies to the majority of the population with CKD. In 
addition to these traditional factors, the patient with CKD is exposed 
to other cardiovascular risk factors, e.g. anaemia, bone-mineral disorder, 
infl ammation and oxidative stress.(3) The prevalence of these “non-
traditional” risk factors increases as GFR worsens (Table 2).
TABLE 1: Stages of chronic kidney disease (K/DOQI)*
 1 Kidney damage + normal or     GFR ≥ 90
 2 Mild     in GFR 60-89
 3 Moderate     in GFR 30-59
 4 Severe     in GFR 15-29
 5 Kidney failure < 15
Stage
* Adapted from Kidney Disease Outcomes Quality Initiative, Am J Kidney Dis Suppl 1 2002;39:SI-S246.
Description GFR (ml/min/1.73m2)
TABLE 2: Risk factors for cardiovascular disease (CVD) in chronic kidney disease (CKD)
Diabetes Hypervolaemia Homocysteine
Smoking Anaemia Infl ammation
Dyslipidaemia Bone mineral disorder Oxidative Stress
Sedentary Lifestyle Hyperdynamic circulation
Obesity due to large A-V fi stulae 
Classical Non classical – related to kidney disease
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As a result, patients with CKD are commonly affected by excess CV 
morbidity and mortality.(4,5) CV mortality rates may be as high as 50%. 
Even stable patients with a moderate degree of severity (CKD stage 3, 
GFR <60 ml/min) have a high prevalence of CVD.(6) Goicoechea et al. 
showed that age and previous coronary artery disease, the traditional 
CV risk factors, accurately predicted cardiovascular events in these 
patients(6). 
Although the subsequent discussion will focus on those patients with a 
GFR <60 ml/min, it is important to stress that, even at an early stage, 
with increasing amounts of albuminuria (from within the low normal 
range) to the subsequent development of overt proteinuria, the patient 
is at increasing risk of coronary heart disease.(7,8) It appears that this 
albuminuria/proteinuria is independent of traditional risk factors and is 
a marker of endothelial dysfunction. It is postulated that it is this 
endothelial cell dysfunction that permits entry of atherogenic 
lipoproteins into the media of the blood vessels.(9) 
TRADITIONAL CARDIOVASCULAR RISK FACTORS     
Obesity
There is a paradox, called “reverse epidemiology”, wherein a high body 
mass index (BMI) is better for long-term survival in patients on chronic 
haemodialysis.(10) Beddhu has shown that haemodialysis patients with a 
high BMI have increased infl ammatory markers (elevated CRP levels) 
and atherosclerosis.(10) Yet their survival is better than those with a 
lower BMI. The phenomenon is explained by hypothesising that good 
nutrition overwhelms the negative impact of atherosclerosis. 
Malnutrition, on the other hand, offers no “buffer” for these patients and 
is a risk factor for cardiovascular disease. Others suggest that this “risk 
factor paradox” could be as a result of absorption into the adipose 
tissue of uraemic toxins or as a result of a more stable haemodynamic 
state, or unique neurohormonal constellations or reverse causation.(11).
Dyslipidaemia
There are numerous publications on the pathogenesis of the 
dyslipidaemia of CKD. A summary of proposed causative mechanisms 
includes the existence of insulin resistance, the presence of low oncotic 
pressure stimulation of the hepatocytes, as well as delayed metabolism 
because of reduced lipoprotein lipase and hepatic triglyceride lipase 
activity. The pool of lipoprotein lipase is reduced in nephrotic syndrome 
patients. Malnutrition plays a role in reducing the cholesterol level in 
CKD patients. 
The important disturbances in serum lipids and apoproteins are shown 
in Table 3.  From this table it can clearly be seen that increased 
cholesterol, increased LDL cholesterol and low HDL is not found in 
CKD patients (except in nephrotics). However, despite normal or low 
levels of LDL cholesterol and total cholesterol, atherosclerosis is very 
prevalent in these patients. Baigent and Landray ascribe this phenomenon 
to “confounding by disease” or “reverse causality”.(12) In support of 
“confounding by disease” they point to work done by Sarnak and Levey 
who show that the association of many risk factors, in concert, impinge 
on cardiovascular mortality/morbidity.(13) The point is made that, in this 
soup of metabolic derangement, the LDL cholesterol need not be 
abnormally high to be a CV risk factor. 
There is increasing evidence to show that lipoprotein(a) is degraded by 
the normal functioning kidney. Consequently levels increase with 
deteriorating renal function. Elevated levels of lipoprotein(a) are 
associated with an increased incidence of atherosclerotic events in 
dialysis patients.(14)
Hypertension
This must be the most important traditional risk factor associated with 
CVD. Not only is the incidence of stroke and CVD increased in the 
presence of hypertension(15), but CKD progression to end-stage is 
accelerated by uncontrolled blood pressure.(1)
Lewington et al. demonstrated a doubling of risk for stroke and coronary 
artery disease for every 20 mm Hg increase in systolic pressure above 
120 mmHg.(15) 
The diseased kidney has an increased propensity to retain sodium. It 
has been suggested that the kidney is the universal cause of hypertension. 
For example, merely having a reduced number of nephrons predisposes 
that individual to the development of hypertension.(16,17) This situation is 
found in those with low birth weights.
NON-TRADITIONAL CARDIOVASCULAR RISK        
FACTORS
Bone-mineral disorder (BMD)
The diseased kidney’s inability to excrete excessive dietary inorganic 
phosphate is the major cause of the BMD. In addition, the accompanying 
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TABLE 3: Dyslipidaemia in chronic kidney disease (CKD)
     Cholesterol Normal Cholesterol 
     Triglycerides      Triglycerides 
     LDL Cholesterol Normal/mildly     LDL Cholesterol
     apo B, C-11 and E      apo (a)
     HDL Cholesterol       or normal HDL Cholesterol
Nephrotic Non-nephrotic
inability of the diseased kidney to hydroxylate 25-hydroxycholecalciferol 
to active Vitamin D3, limits calcium absorption with consequent 
hypocalcaemia. These three abnormalities, i.e. hyperphosphataemia, 
hypocalcaemia and decreased levels of active Vitamin D3, will result in 
the increased release of parathyroidhormone (PTH). PTH mobilizes 
calcium and phosphate from the gut and bone which will aggravate an 
already hyperphosphataemic state. 
The increase in phosphate levels predisposes to the precipitation of 
calcium phosphate crystals in the media of the walls of the vessels.(18,19) 
In an elegant study on the rat model, Verberckmoes et al. found calcium 
phosphate and whitlockite crystals in the aortas of uraemic animals.(18) 
The use of X-ray fl uorescence mapping with integration of the 
diffraction patterns in the scanned areas in the rats’ aortas, revealed 
calcium phosphate (CaHPO4.2H2O) as an amorphous substance, 
apatite Ca10(PO4)6(OH)2 and whitlockite [(Mg,Ca)3(PO4)]2. Whitlockite 
and apatite are insoluble.(19) Whitlockite was found only in those animals 
treated with Vitamin D3. Vitamin D3 increases the absorption of 
magnesium (Mg) which subsequently then favours the formation of the 
insoluble whitlockite. 
High phosphate levels also stimulate the differentiation of vascular 
smooth muscle cells into osteoblasts.(20) Therefore, the CKD patient has 
the ability to form “bone” in the vessels. Increased Ca/Phosphate 
product, hyperparathyroidism and increased phosphate levels have 
been associated with an increased risk of coronary artery calcifi cation.(21). 
The data published by Goodman et al. confi rmed the prevalence of 
early coronary artery calcifi cation, as determined by electron beam 
tomography, in young adults on dialysis. They also pointed to the dangers 
of calcium carbonate as a phosphate binder, a high calcium/phosphate 
product and length of time on dialysis.
The development of medial and intimal sclerosis in vessel walls results 
in both arteriosclerosis and atherosclerosis. The resultant “stiff ” wall is 
non-compliant, producing an increased pulse wave velocity and systolic 
hypertension. It is not unusual to see CKD patients treated on dialysis 
with blood pressure readings of 210/70 mmHg. 
Figure1 illustrates an example of both large and small vessel calcifi cation. 
A rare complication of small vessel calcifi cation produces systemic 
calciphylaxis, with skin infarction and progressive ischemic destruction 
of the subcutaneous tissue (Figure 2). Soft tissue too is involved by 
calcium/phosphate deposition. Figure 3 shows this phenomenon where 
“waves” of calcifi cation can be seen in the muscles of the upper leg. 
Patients may develop rapidly progressive heart valve calcifi cation. 
Ultrafi ltration during haemodialysis may be limited by marked falls in 
blood pressure or patients may develop pulmonary oedema. Many of 
these patients may not have overtly abnormal serum biochemical 
profi les. 
Infl ammation/oxidative stress
In order to explain the exaggerated prevalence of CVD in patients with 
CKD, when compared with those without kidney disease, the 
infl ammation/oxidative stress phenomenon has been proposed as a 
possible additional pathogenetic mechanism. The “confounding by 
disease” theory(12) allows for debate around the immeasurable process 
of oxidative stress. The “stress” has been defi ned as too much damage 
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 FIGURE 1: an example of both large and small vessel calciﬁ cation. 
 FIGURE 3: A rare complication of small vessel calciﬁ cation produces systemic 
calciphylaxis, with skin infarction and progressive ischemic destruction of the 
subcutaneous tissue.
 FIGURE 3: Waves of calciﬁ cation can be seen in the muscles of the upper leg.
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to tissues because of too little control.(22) The damage is infl icted by 
oxidants which are normally used to protect cells from toxins and 
organisms, but their control, i.e. antioxidant activity, is lacking or inferior. 
In the uraemic state, the stimulation of the production of oxidants is 
unchecked and infl ammation occurs, with little repair. Under these 
circumstances atherosclerosis develops. No direct mention is made of 
arteriosclerosis, but it must be assumed, as for atherosclerosis, that it is 
similarly infl uenced by oxidant cell damage. 
Macrophages and polymorphonuclear neutrophils produce reactive 
oxygen species (ROS).(23) O2 is reduced to the superoxide anion, which 
is immediately changed to hydrogen peroxide (H2O2). The secretion of 
these oxidants is accompanied by cytokine release, which further 
impacts on the infl ammatory response (and causes injury). The 
endothelial cell is another source of ROS but is also the major target of 
these oxidants.(23) Endothelial cell dysfunction permits increasing 
albuminuria and eventually overt proteinuria, and may allow atherogenic 
lipids to get into the vessel walls.
The depleted and ineffi cient anti-oxidant system in CKD comprises, 
amongst others, superoxide dismutase, vitamin E, vitamin C, ferritin, 
transferrin and albumin.(23) More still needs to be learnt about the role 
of these processes in increasing the CV disease risk. 
ARRHYTHMIAS                                                                   
The risk of arrhythmias in CKD is high.(24) Sudden cardiac death (SCD) 
is more prevalent in this group because of the presence of hyperkalaemia. 
This should be the overriding concern of all who manage these patients. 
Gussak and Gussak(25) propose that the problem is more complex and 
point to the development of K+ channelopathies in CKD, where 
coronary artery disease (CAD), left ventricular hypertrophy (LVH) and 
congestive heart failure (CHF) are associated with a decreased number 
of ion channels (“diminished repolarisation reserve”) but a 
correspondingly increased sensitivity in the remaining channels. This 
leads to the development of the acquired long QT syndrome (LQTS)(25) 
with the risk of torsades de points and SCD.(25)
The risk of acquired LQTS is increased by the administration of drugs 
which prolong the QT interval. This is particularly relevant in the patient 
with CKD when the drug is wholly, or even partially, excreted by the 
kidneys. 
In haemodialysis patients, the arrhythmias are thought to be related to 
a brief period of intracellular hypokalaemia and/or hypomagnesaemia 
whilst on dialysis.(26) Longer dialysis times with a gentler ultrafi ltration 
prescription and a higher K+ concentration in the dialysate fl uid may be 
the solution.
THE TREATMENT OF CARDIOVASCULAR DISEASE   
The diagnosis of the acute coronary syndrome (ACS) in CKD is 
dependent on classical clinical symptoms and signs. ECG evidence is 
crucial when changes from earlier tracings are evident or obvious ST 
segment changes are present. It is now well known that cardiac troponin 
T (cTnT) is elevated in approximately 25% of asymptomatic patients 
with CKD. Its only value, in the setting of acute chest pain, is if the level 
is within the normal range and myocardial infarction can therefore be 
excluded. However, Goicoechea et al. have shown that cTnT too is a 
predictor of CV events.(6)  Their suggestion that further CV investigations 
in persons with increased cTnT be undertaken, may be useful. They are 
supported by an earlier study which concluded that cTnT elevations 
were associated with advanced coronary artery disease in asymptomatic 
patients.(27) 
De Zeeuw(7,28) and others point out that increasing albuminuria 
precedes overt renal disease and CVD risk. Angiotensin converting 
enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs), 
by succeeding in reducing albuminuria, also succeed in preserving renal 
function. They are also cardioprotective. Therefore the use of ACE-Is 
and ARBs is recommended in patients with increasing albuminuria, 
overt proteinuria and CKD. More recently, a total blockade of the RAAS 
has been suggested, whereby an aldosterone antagonist is also 
prescribed. It was shown that spironolactone may reduce proteinuria 
and slow progression in patients with CKD.(29) Careful monitoring of K+ 
levels in patients receiving combinations of these drugs is mandatory.
Control of blood pressure (BP) is very important and is linked to 
slowing of progression of kidney disease, improved cardiac outcomes 
and stroke prevention. In the post-hoc analysis of the HOPE study, an 
ACE-I provided near equal protection against CV events in CKD 
patients as it did in those with normal renal function.(30) 
There is ongoing debate on how best to measure BP in CKD. In essential 
hypertension, ambulatory BP recording better predicts CV mortality 
and morbidity than clinic readings.(31) In 277 patients with CKD (mean 
creatinine approximately 180 umol/l), predominantly white men who 
were elderly and generally obese (average BMI 30.5) and including 
diabetics (36.9%), ambulatory BP recordings provided more prognostic 
information than clinic BP measurements.(32) Systolic BP predicted 
ESRD compared to total mortality. Night ambulatory BP predicted 
total mortality. There are only a few such studies in CKD patients, 
e.g. Liu et al. pointed to non-dipping as being associated with 
cardiovascular deaths in haemodialysis patients.(33) 
Two major publications have recently pointed out the fact that there is 
very little evidence from controlled studies to give guidance on the 
treatment of cardiovascular events in patients with CKD.(34,35) 
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Approximately 75%-80% of trials examining different coronary artery 
disease therapies published between 1998 and 2005 excluded patients 
with CKD.(34) Standard therapy for coronary artery disease may 
therefore not be effective in patients with CKD. In addition to 
atherosclerosis, there is also arteriosclerosis and an abnormal metabolic 
state, all of which may necessitate a different strategy. Patients with 
CKD need to be included in future intervention studies to answer 
these diffi cult management questions.
Edwards et al. provide an excellent review on the treatment of coronary 
artery disease in CKD.(35) They concede the lack of evidence-based 
medicine. Referring to patients with CKD, they make the following 
points:
■  The benefi cial effects of statin therapies are uncertain; however, 
retrospective examination of data suggests that statin therapy may 
provide effects similar to those found in patients with normal renal 
function. So, unless contraindicated, a lipid lowering agent for 
secondary prevention is indicated. Caution must be exercised in 
CKD, since rhabdomyolysis is a common complication with the use 
of stains or fi brates. The SHARP (Study of Heart and Renal 
Protection) study hopefully will give some fi nality when the results 
are published (in 2008). 
■  The use of beta blockers following ST segment elevation myocardial 
infarction (STEMI) in CKD patients on haemodialysis is of great 
advantage and is to be recommended. It must also be remembered 
that dialysis is a state of great sympathetic over-activity with 
prominent catecholamine release. 
■  The revascularisation of coronary arteries by CABG seems to be 
better than medical treatment or angioplasty. This is not unexpected, 
since there are metabolic forces in CKD which unrelentingly calcify 
tissue and stiffen arterial walls. 
■  Stenting has offered a ray of hope for those patients with an 
improved long-term prognosis. The PRESTO study is quoted(36) 
wherein event rates were low and not infl uenced by GFR. Crude 
mortality was elevated in the lowest GFR group, but after adjusting 
for co-morbidity, the difference was insignifi cant. There has been 
much discussion on the virtues of drug eluting (anti-proliferative) 
stents versus non-eluting stents. CKD has not been specifi cally 
addressed. 
TREATMENT OF THE BONE–MINERAL DISORDER        
An in-depth discussion of this complex issue is beyond the scope of this 
article. In brief, all attempts must be made to stop the relentless invasion 
of tissue by calcium and phosphate crystals. The abnormal blood 
biochemistry, elevated inorganic phosphate and PTH levels, may occur 
during the early stages of CKD. The treatment at these earlier stages is 
uncertain. There are cost implications, as well as exposure to excessive 
calcium (through calcium-containing phosphate binders and the use of 
vitamin D) to consider in designing the treatment strategy. Taking 
calcium carbonate and vitamin D for many years risks excessive 
exposure to calcium and the possibility of eventual vascular calcifi cation. 
The treatment of these biochemical abnormalities must be individualised, 
preferably with input from a nephrologist. 
TREATMENT OF OBESITY                                                  
The fact that there appears to be an improved survival of obese 
patients on haemodialysis does not mean that it should be encouraged 
in the lead-up to dialysis. What it does suggest is that malnutrition and 
very low BMIs should be avoided, hence caution is indicated in advising 
protein restriction in an attempt to delay the progression of CKD. 
Progression to stage 5 CKD (ESRD) is accelerated in obesity; it is 
associated with insulin resistance, diabetes and hypertension, and is a 
defi ning factor for the metabolic syndrome. The metabolic syndrome is 
a risk factor for CVD.(37) Every effort should therefore be made to 
avoid obesity but not permit the development of excessive loss of 
weight or malnourishment.
CONCLUSION                                                                     
CKD is clearly a major risk factor for CVD. The traditional risk factors 
should be managed according to current guidelines. ACE-Is and ARBs 
must remain the mainstay of treatment of hypertension, and should 
also be used to reduce proteinuria and to slow the progression to end-
stage kidney disease. 
In the patient with CKD, bone-mineral disorder is particularly relevant 
in contributing to vascular disease, and its management requires long-
term surveillance by an experienced physician or nephrologist.
Randomised controlled studies are awaited to assess the best approach 
to CKD patients with coronary artery disease. As these patients have 
been excluded from most major intervention studies, the only 
information available is derived from registries or smaller controlled 
studies. 
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